P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy
- PMID: 33818742
- PMCID: PMC8155152
- DOI: 10.1007/s11302-021-09783-w
P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy
Conflict of interest statement
FDV is a member of the Scientific Advisory Board of Biosceptre Ltd, a Biotech Company involved in the development of P2X7-targeting antibodies.
Alba Clara Sarti declares that she has no conflict of interest.
Valentina Vultaggio-Poma declares that she has no conflict of interest.
References
- 
    - Douguet L, Janho dit Hreich S, Benzaquen J, Seguin L, Juhel T, Dezitter X, Duranton C, Ryffel B, Kanellopoulos J, Delarasse C, Renault N, Furman C, Homerin G, Féral C, Cherfils-Vicini J, Millet R, Adriouch S, Ghinet A, Hofman P, Vouret-Craviari V. A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat Commun. 2021;12(1):653. doi: 10.1038/s41467-021-20912-2. - DOI - PMC - PubMed
 
- 
    - Di Virgilio F, Bronte V, Collavo D, Zanovello P (1989) Responses of mouse lymphocytes to extracellular adenosine 5'-triphosphate (ATP). Lymphocytes with cytotoxic activity are resistant to the permeabilizing effects of ATP. J Immunol 143(6):1955–1960 - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Other Literature Sources
- Medical
 
        